The Australasian Myeloma Research Consortium (AMaRC) in collaboration with the
Australasian Leukaemia & Lymphoma Group (ALLG) and the Myeloma and Related Diseases
Registry (MRDR) is conducting a phase II study to investigate the optimal usage of
lenalidomide and/or bortezomib in newly-diagnosed transplant-ineligible myeloma patients
based on a frailty score (frailty is characterised by a decline in body functions).
If you are a patient recently diagnosed with myeloma or a haematologist and would like to
know more about this study, then please contact AMaRC at amarc@alfred.org.au for general
information.